Cardiex’s arterial health tech transforms Apple’s new blood pressure feature into actionable clinical data

• Apple’s new Watch alerts users to possible hypertension, but Cardiex’s CONNEQT Pulse delivers FDA-cleared data doctors need to diagnose and treat it
• The Pulse provides clinical-grade confirmation with structured cardiology reports and arterial biomarkers
• The device enables full Apple Health integration for seamless physician access

Special Report: Cardiex has confirmed its Pulse device is fully compatible with Apple’s newly announced hypertension detection features.

Cardiex (ASX:CDX) subsidiary CONNEQT Health, a global player in arterial health technology, has announced that the CONNEQT Pulse, an FDA-cleared and Validated Device Listing (VDL)-listed blood pressure and arterial health monitoring system, is fully compatible with Apple’s newest hypertension detection features, recently announced for Series 11 and Ultra 3 Apple Watches.

As Apple introduces hypertension notifications that could identify over one million undiagnosed cases in the first year, the Pulse system provides the additional clinical-grade confirmation that Apple Watch users and healthcare providers require for accurate diagnosis and treatment decisions.

With hypertension affecting over 1.3 billion people globally and serving as the leading preventable cause of heart attack and stroke, the combination of Apple’s detection capability and the Pulse’s clinical confirmation addresses a critical gap in preventive healthcare.

Apple’s hypertension notifications represent a major advancement in preventive health technology, using passive monitoring through optical heart sensors to detect potential high blood pressure over 30-day periods.

However, Apple emphasises that these notifications are “possible” alerts requiring confirmation with validated blood pressure measurements – which is where the CONNEQT Pulse comes in.

“Apple has created an opportunity to catch hypertension before it causes damage,” said CONNEQT Health CEO Craig Cooper.

“Our Pulse monitor transforms those alerts into the validated clinical data that Watch users and doctors need to make informed treatment decisions. We’re not just measuring blood pressure – we’re completing Apple’s vision for proactive heart health.”

Apple Watch flags the possibility – Cardiex’s Pulse delivers the proof

Apple’s new FDA-cleared Watch feature can detect signs of possible hypertension based on 30 days of continuous optical data. But for a clinical diagnosis, more is needed. The CONNEQT Pulse steps into that gap as a validated medical device that provides the diagnostic-grade data doctors require to confirm and treat high blood pressure.

The Watch monitors photoplethysmographic (PPG) signals over 30 days to flag abnormal blood pressure trends. It’s an alert system but not a diagnostic tool. Apple is clear that users need to follow up with a validated device to confirm risk. In addition, the Watch requires ongoing calibration with a validated blood pressure device in order for it to work.

Earlier this year, Cardiex also announced full Apple Health integration which means Pulse syncs heart rate and brachial pressure data to Apple Health. It creates a seamless user experience where early alerts and clinical proof live together.

Unlike standard home devices that only measure brachial pressure, the CONNEQT Pulse captures a wide range of cardiovascular biomarkers used by cardiologists worldwide:

• Central Blood Pressure – the pressure at the heart and major organs, considered a better predictor of heart attack and stroke than brachial pressure alone.
• Arterial Stiffness – a key early marker of vascular aging and cardiovascular risk, measured via pulse wave velocity.
• SEVR (Subendocardial Viability Ratio) – a clinical indicator of whether your heart’s oxygen supply is keeping up with its workload.
• Brachial Blood Pressure – the traditional arm measurement required by most physicians and used in standard practice.
• Morning and Evening Averages – detects variability and white-coat effects, providing a clearer, more comprehensive picture of blood pressure behaviour across the day.
• Apple Health Sync – ensures all data is integrated into a single health record, alongside Watch alerts, for easy review by both users and clinicians.

Unlike conventional cuffs that deliver isolated readings, the Pulse further generates two clinically meaningful outputs. The On-Demand Assessment offers an immediate, structured report of arterial status, while the 30-Day Cardiology Report summarises long-term trends in pressure, load, and variability. Together, they provide a deeper, diagnostic-quality view of arterial health, turning everyday measurements into data physicians can act on.

Apple’s hypertension alert is FDA-cleared, but it’s a screening tool and not a diagnosis. The Pulse is FDA-cleared and VDL-listed for diagnostic use. Together, they close the loop.

This article was developed in collaboration with Cardiex, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.